Ipsen Biopharmaceuticals, Inc.
IPSEYDrugs in Pipeline
62
Phase 3 Programs
40
Upcoming Catalysts
12
Next Catalyst
This month
Market Overview
Stock performance and key metrics
12 upcoming, 2 past
Odevixibat Phase 3 Est. Readout
Estimated primary completion for Odevixibat trial (NCT04336722) in Biliary Atresia. Topline data typically follows completion by weeks to months.
SourceElafibranor Phase 3 Est. Readout
Primary completion for Elafibranor trial (NCT06383403) in Primary Biliary Cholangitis
Source10 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Botulinum toxin type A
Glabellar Frown Lines
Triptorelin (I.N.N.)
Precocious Puberty
Smecta (Diosmectite), duration of treatment - 7 days
Diarrhoea
Triptorelin Pamoate
Central Precocious Puberty
Lanreotide Autogel
Intestinal Obstruction
EGb 761® (Tanakan®)
Multiple Sclerosis, Relapsing-Remitting
EGb761
Stroke, Acute
mecasermin
Growth Hormone Insensitivity Syndrome
BLI800
Diagnosis Disease
PEG 4000 (Forlax®)
Chronic Constipation
Triptorelin embonate 22.5 mg
Prostate Cancer
Triptorelin Pamoate PR 3-month
Endometriosis
A4250 (odevixibat)
Progressive Familial Intrahepatic Cholestasis
Pegvisomant
Acromegaly
Elafibranor 80mg
Primary Biliary Cirrhosis
rhIGF-1 (mecasermin, Tercica, Inc.)
Growth Disorders
Eziclen
Bowel Cleansing
rhIGF-1 (mecasermin) for a period of 86 weeks
Insulin-Like Growth Factor-1 Deficiency
Irinotecan Liposomal Injection
Metastatic Adenocarcinoma of the Pancreas
Lanreotide
Carcinoid Syndrome
Eziclen®/Izinova®
Digestive System Disease
Triptorelin pamoate 15mg
Central Precocious Puberty
Lanreotide microparticles
Digestive Fistulae
Somatropin (rDNA origin)
Turner Syndrome
Lanreotide Autogel®
Acromegaly
Triptorelin pamoate (embonate) salt
Advanced Prostate Cancer
Elafibranor
Primary Biliary Cholangitis
Lanreotide autogel 120 mg
Acromegaly
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
Acromegaly
Lanreotide (microparticle formulation)
Intestinal Obstruction
Lanreotide (Autogel formulation)
Acromegaly
Somatuline Autogel (lanreotide acetate)
Acromegaly
Odevixibat
Biliary Atresia
IPN10200
Moderate to Severe Upper Facial Lines
Triptorelin Pamoate 11.25mg
Prostate Cancer
Triptorelin pamoate 11.25mg (Decapeptyl® SR)
Precocious Puberty
lanreotide (Autogel formulation), duration of treatment 46-48 weeks
Acromegaly
Irinotecan liposome injection
Small Cell Lung Cancer
Triptorelin (Decapeptyl®)
Prostate Cancer
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP)
Diflomotecan (BN80915)
Small Cell Lung Cancer
Lanreotide PRF
Acromegaly
IPN01195
Advanced Solid Tumor
nal-IRI
Pancreatic Cancer
IPN60300
Locally Advanced Solid Tumor
Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Prostate Cancer
BN83495
Endometrial Cancer
Satoreotide trizoxetan 5-20μg
Gastro-Enteropancreatic Neuroendocrine Tumor
IPN01203
Advanced Solid Tumor
Elafibranor 80 mg
Primary Sclerosing Cholangitis
Lidocaine
Chronic Scar Pain
Dysport
Spasticity
Ritivixibat
Primary Sclerosing Cholangitis
Tasquinimod
Advanced or Metastatic Hepatocellular Cancer
Cabozantinib
Locally Advanced or Metastatic Renal Cell Carcinoma
satoreotide trizoxetan
Gastroenteropancreatic Neuroendocrine Tumors
EGb 761 120 mg
Friedreich Ataxia
IPN10200 dose A
Episodic Migraine
Temozolomide (TMZ)
Gastroenteropancreatic Neuroendocrine Tumors
Lanreotide (Autogel formulation) and Temozolomide
Neuroendocrine Tumours
IPN01194
Melanoma
EGb761®
Alzheimer's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Botulinum toxin type A | Phase 3 | Glabellar Frown Lines | - | - |
Triptorelin (I.N.N.) | Phase 3 | Precocious Puberty | - | - |
Smecta (Diosmectite), duration of treatment - 7 days | Phase 3 | Diarrhoea | - | - |
Triptorelin Pamoate | Phase 3 | Central Precocious Puberty | - | - |
Lanreotide Autogel | Phase 3 | Intestinal Obstruction | - | - |
EGb 761® (Tanakan®) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
EGb761 | Phase 3 | Stroke, Acute | - | - |
mecasermin | Phase 3 | Growth Hormone Insensitivity Syndrome | - | - |
BLI800 | Phase 3 | Diagnosis Disease | - | - |
PEG 4000 (Forlax®) | Phase 3 | Chronic Constipation | - | - |
Triptorelin embonate 22.5 mg | Phase 3 | Prostate Cancer | - | - |
Triptorelin Pamoate PR 3-month | Phase 3 | Endometriosis | - | - |
A4250 (odevixibat) | Phase 3 | Progressive Familial Intrahepatic Cholestasis | - | - |
Pegvisomant | Phase 3 | Acromegaly | - | - |
Elafibranor 80mg | Phase 3 | Primary Biliary Cirrhosis | - | - |
rhIGF-1 (mecasermin, Tercica, Inc.) | Phase 3 | Growth Disorders | - | - |
Eziclen | Phase 3 | Bowel Cleansing | - | - |
rhIGF-1 (mecasermin) for a period of 86 weeks | Phase 3 | Insulin-Like Growth Factor-1 Deficiency | - | - |
Irinotecan Liposomal Injection | Phase 3 | Metastatic Adenocarcinoma of the Pancreas | - | - |
Lanreotide | Phase 3 | Carcinoid Syndrome | - | - |
Eziclen®/Izinova® | Phase 3 | Digestive System Disease | - | - |
Triptorelin pamoate 15mg | Phase 3 | Central Precocious Puberty | - | - |
Lanreotide microparticles | Phase 3 | Digestive Fistulae | - | - |
Somatropin (rDNA origin) | Phase 3 | Turner Syndrome | - | - |
Lanreotide Autogel® | Phase 3 | Acromegaly | - | - |
Triptorelin pamoate (embonate) salt | Phase 3 | Advanced Prostate Cancer | - | - |
Elafibranor | Phase 3 | Primary Biliary Cholangitis | - | - |
Lanreotide autogel 120 mg | Phase 3 | Acromegaly | - | - |
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval | Phase 3 | Acromegaly | - | - |
Lanreotide (microparticle formulation) | Phase 3 | Intestinal Obstruction | - | - |
Lanreotide (Autogel formulation) | Phase 3 | Acromegaly | - | - |
Somatuline Autogel (lanreotide acetate) | Phase 3 | Acromegaly | - | - |
Odevixibat | Phase 3 | Biliary Atresia | - | - |
IPN10200 | Phase 3 | Moderate to Severe Upper Facial Lines | - | - |
Triptorelin Pamoate 11.25mg | Phase 3 | Prostate Cancer | - | - |
Triptorelin pamoate 11.25mg (Decapeptyl® SR) | Phase 3 | Precocious Puberty | - | - |
lanreotide (Autogel formulation), duration of treatment 46-48 weeks | Phase 3 | Acromegaly | - | - |
Irinotecan liposome injection | Phase 3 | Small Cell Lung Cancer | - | - |
Triptorelin (Decapeptyl®) | Phase 3 | Prostate Cancer | - | - |
Palovarotene | Phase 3 | Fibrodysplasia Ossificans Progressiva (FOP) | - | - |
Diflomotecan (BN80915) | Phase 2 | Small Cell Lung Cancer | - | - |
Lanreotide PRF | Phase 2 | Acromegaly | - | - |
IPN01195 | Phase 2 | Advanced Solid Tumor | - | - |
nal-IRI | Phase 2 | Pancreatic Cancer | - | - |
IPN60300 | Phase 2 | Locally Advanced Solid Tumor | - | - |
Triptorelin Pamoate (Pamorelin® LA 11.25 mg) | Phase 2 | Prostate Cancer | - | - |
BN83495 | Phase 2 | Endometrial Cancer | - | - |
Satoreotide trizoxetan 5-20μg | Phase 2 | Gastro-Enteropancreatic Neuroendocrine Tumor | - | - |
IPN01203 | Phase 2 | Advanced Solid Tumor | - | - |
Elafibranor 80 mg | Phase 2 | Primary Sclerosing Cholangitis | - | - |
Lidocaine | Phase 2 | Chronic Scar Pain | - | - |
Dysport | Phase 2 | Spasticity | - | - |
Ritivixibat | Phase 2 | Primary Sclerosing Cholangitis | - | - |
Tasquinimod | Phase 2 | Advanced or Metastatic Hepatocellular Cancer | - | - |
Cabozantinib | Phase 2 | Locally Advanced or Metastatic Renal Cell Carcinoma | - | - |
satoreotide trizoxetan | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors | - | - |
EGb 761 120 mg | Phase 2 | Friedreich Ataxia | - | - |
IPN10200 dose A | Phase 2 | Episodic Migraine | - | - |
Temozolomide (TMZ) | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors | - | - |
Lanreotide (Autogel formulation) and Temozolomide | Phase 2 | Neuroendocrine Tumours | - | - |
IPN01194 | Phase 2 | Melanoma | - | - |
EGb761® | Phase 2 | Alzheimer's Disease | - | - |